251 related articles for article (PubMed ID: 21638942)
41. Erlotinib and maintenance therapy of non-small cell lung cancer. Inadequate assessment; authorisation unjustified.
Prescrire Int; 2011 Oct; 20(120):234. PubMed ID: 21970082
[No Abstract] [Full Text] [Related]
42. Molecular on/off switch.
Milton DT; Riely GJ; Pao W; Miller VA; Kris MG; Heelan RT
J Clin Oncol; 2006 Oct; 24(30):4940-2. PubMed ID: 17050880
[No Abstract] [Full Text] [Related]
43. First-line erlotinib inferior to chemo in advanced lung cancer.
Oncology (Williston Park); 2012 Oct; 26(10):930-1. PubMed ID: 23176004
[No Abstract] [Full Text] [Related]
44. Erlotinib: optimizing therapy with predictors of response?
Goodin S
Clin Cancer Res; 2006 May; 12(10):2961-3. PubMed ID: 16707589
[No Abstract] [Full Text] [Related]
45. [Tyrosine kinase inhibitor erlotinib (Tarceva) improves survival of patients with multiple previous treatments].
Krankenpfl J; 2004; 42(5-6):158. PubMed ID: 15527222
[No Abstract] [Full Text] [Related]
46. [Mutations in the epidermal growth factor receptor and targeted therapy of non-small-cell lung cancer].
Lai RS; Xie L; Shen LS; He YM; Zhu CL
Zhonghua Bing Li Xue Za Zhi; 2005 Nov; 34(11):745-6. PubMed ID: 16536324
[No Abstract] [Full Text] [Related]
47. Two cases of psoriasis responding to erlotinib: time to revisiting inhibition of epidermal growth factor receptor in psoriasis therapy?
Overbeck TR; Griesinger F
Dermatology; 2012; 225(2):179-82. PubMed ID: 23095682
[TBL] [Abstract][Full Text] [Related]
48. Lung cancer: looking ahead in 2004.
Belani CP; Ramalingam S
Clin Lung Cancer; 2004 Jan; 5(4):200. PubMed ID: 14967070
[No Abstract] [Full Text] [Related]
49. Gefitinib versus cetuximab in lung cancer: round one.
Minna JD; Peyton MJ; Gazdar AF
J Natl Cancer Inst; 2005 Aug; 97(16):1168-9. PubMed ID: 16106015
[No Abstract] [Full Text] [Related]
50. EGFR mutation status and prognosis for gefitinib treatment in Japanese lung cancer.
Sasaki H; Endo K; Mizuno K; Yano M; Fukai I; Yamakawa Y; Fujii Y
Lung Cancer; 2006 Jan; 51(1):135-6. PubMed ID: 16314000
[No Abstract] [Full Text] [Related]
51. Epidermal growth factor receptor mutations in non-small cell lung cancer: predicting clinical response to kinase inhibitors.
Sequist LV; Haber DA; Lynch TJ
Clin Cancer Res; 2005 Aug; 11(16):5668-70. PubMed ID: 16115901
[No Abstract] [Full Text] [Related]
52. First-generation epidermal growth factor receptor tyrosine kinase inhibitors in EGFR mutation: positive non-small cell lung cancer patients.
Sequist LV
J Thorac Oncol; 2008 Jun; 3(6 Suppl 2):S143-5. PubMed ID: 18520299
[TBL] [Abstract][Full Text] [Related]
53. The "lazarus response" in treatment-naive, poor performance status patients with non-small-cell lung cancer and epidermal growth factor receptor mutation.
Langer CJ
J Clin Oncol; 2009 Mar; 27(9):1350-4. PubMed ID: 19224840
[No Abstract] [Full Text] [Related]
54. [I. What is the Standard Treatment of EGFR-TKIs? Did EGFR-TKIs Improve Treatment for Non-Small Cell Lung Cancer?].
Urata Y; Satouchi M
Gan To Kagaku Ryoho; 2015 Aug; 42(8):931-4. PubMed ID: 26353389
[No Abstract] [Full Text] [Related]
55. Point: should epidermal growth factor receptor mutations be routinely tested for in patients with lung cancer? Yes.
Sterman DH
Chest; 2013 Mar; 143(3):597-600. PubMed ID: 23460149
[No Abstract] [Full Text] [Related]
56. Gefitinib first or gefitinib second: is timing everything in the treatment of EGFR mutant non-small cell lung cancer?
Jänne PA
Am J Respir Crit Care Med; 2008 Oct; 178(8):783-5. PubMed ID: 18832554
[No Abstract] [Full Text] [Related]
57. Targeted kinase inhibitors in lung cancer: from EGFR to patients.
Apolone G; La Vecchia C; Garattini S
Eur J Cancer; 2006 Jan; 42(2):124-5. PubMed ID: 16324837
[No Abstract] [Full Text] [Related]
58. [Is chemotherapy still an option in oncogene-addicted non-small cell lung cancer? No].
Girard N
Bull Cancer; 2015 Jun; 102(6 Suppl 1):S96-9. PubMed ID: 26118885
[TBL] [Abstract][Full Text] [Related]
59. The role of third-generation epithelial growth factor receptor inhibitors in non-small cell lung cancer.
Sequist LV
Clin Adv Hematol Oncol; 2015 Mar; 13(3):147-9. PubMed ID: 26352419
[No Abstract] [Full Text] [Related]
60. EGFR mutations and sensitivity to gefitinib.
Rossi G; Marchioni A; Longo L
N Engl J Med; 2004 Sep; 351(12):1260-1; author reply 1260-1. PubMed ID: 15376351
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]